Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
Conditions: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye; Ocular Hypertension (OHT) Interventions: Drug: Experimental: QLS-111 ophthalmic solution, (0.015%); Drug: Experimental: QLS-111 ophthalmic solution, (0.03%); Drug: Experimental: QLS-111 ophthalmic solution, (0.075%); Drug: Timolol maleate Preservative Free 0.5% ophthalmic solution; Other: QLS-111 ophthalmic vehicle solu tion Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
The Effect of Labor on Intraocular Pressure Fluctuation in Healthy Eyes
Conditions: Intraocular Pressure; Delivery Intervention: Device: SENSIMED Triggerfish Eye Lenses Sponsor: Faculty Hospital Kralovske Vinohrady Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
Conditions: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye; Ocular Hypertension (OHT) Interventions: Drug: Experimental: QLS-111 ophthalmic solution, (0.015%); Drug: Experimental: QLS-111 ophthalmic solution, (0.03%); Drug: Experimental: QLS-111 ophthalmic solution, (0.075%); Drug: Timolol maleate Preservative Free 0.5% ophthalmic solution; Other: QLS-111 ophthalmic vehicle solu tion Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
The Effect of Labor on Intraocular Pressure Fluctuation in Healthy Eyes
Conditions: Intraocular Pressure; Delivery Intervention: Device: SENSIMED Triggerfish Eye Lenses Sponsor: Faculty Hospital Kralovske Vinohrady Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
Qlaris Phase 2 Study of QLS-111 in POAG and/or OHT Patients
Conditions: Primary Open Angle Glaucoma (POAG); Primary Open Angle Glaucoma of Both Eyes; Primary Open-Angle Glaucoma, Unspecified Eye; Ocular Hypertension (OHT) Interventions: Drug: Experimental: QLS-111 ophthalmic solution, (0.015%); Drug: Experimental: QLS-111 ophthalmic solution, (0.03%); Drug: Experimental: QLS-111 ophthalmic solution, (0.075%); Drug: Timolol maleate Preservative Free 0.5% ophthalmic solution; Other: QLS-111 ophthalmic vehicle solu tion Sponsor: Qlaris Bio, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 30, 2023 Category: Research Source Type: clinical trials
